Grants for County governments - Health

This grant provides funding to organizations that will deploy Starlink satellite internet units to improve connectivity for rural tribal nations in Arizona, enhancing access to essential services and benefits for veterans.

This funding opportunity supports projects that integrate mental health care into healthcare and community settings in low- and middle-income countries, aiming to improve access and quality of mental health services while building local research capacity.

This funding opportunity supports researchers in developing innovative small animal and human cellular models to study the complex interactions between the central nervous system and the immune system in individuals living with HIV who are on antiretroviral therapy.

This funding opportunity supports educational projects that enhance community resilience and environmental literacy in the Gulf States by engaging learners of all ages in addressing local environmental challenges.

This grant provides funding to organizations in South Africa to implement targeted HIV prevention and care programs for high-risk populations, including youth, in various community settings such as schools and workplaces.

This funding opportunity supports the development of innovative tools and systems that help individuals collect and understand their health data to make informed decisions about their health.

The purpose of the NIA Career Transition Award (CTA) is to facilitate the transition of mentored researchers to tenure-track faculty conducting research that advances the mission of NIA. This three-year award provides protected time through salary and research support and is targeted at applicants who plan to start a tenure-track faculty position within a year of the award.

This funding opportunity supports innovative research projects that develop new technologies for cancer analysis, targeting a wide range of applicants including universities, nonprofits, and small businesses.

The Catalyze Product Definition Funding Opportunity Announcement (FOA) offers early-stage financial support for the development and testing of medical device prototypes, identification of disease targets for diagnostics, and creation of research tools to treat heart, lung, blood, and sleep (HLBS) disorders, with the goal of advancing these projects to a stage where they can qualify for the NHLBI Catalyze Preclinical program or secure further development funding from other sources.

This funding opportunity provides financial support to nonprofit organizations in Arizona to deliver direct counseling services to parents grieving the violent loss of their children.

The Indiana Criminal Justice Institute (ICJI) is offering the 2024-2025 Family Violence Prevention and Services Act (FVPSA) American Rescue Plan (ARP) Supplemental Funding Grant. This grant aims to prevent, prepare for, and respond to COVID-19, with a specific focus on increasing access to COVID-19 testing, vaccines, and mobile health units to mitigate the virus's spread and enhance support for domestic violence survivors and their dependents. The program aligns with the mission of supporting community-based projects that effectively aid victims of family violence, domestic violence, and dating violence. The primary beneficiaries of this grant are domestic violence shelters, domestic violence programs, culturally specific organizations, tribes, rural communities, racial and ethnic specific communities, and limited English proficient (LEP) individuals, as well as domestic violence survivors and their dependents. The impact goals are to eliminate barriers to COVID-19 testing and supplies, provide resources for onsite testing, ensure access to rapid testing, maintain and increase testing efforts, expand access to testing for underserved populations, and broaden COVID-19 mitigation activities. The grant prioritizes several key areas, including COVID-19 testing (viral and antibody tests, planning, training, reporting, and supply procurement), COVID-19 mitigation (reducing transmission, case investigation, contact tracing, screening, education, and referrals), and COVID-19 vaccine access (administration, outreach, education, appointment assistance, and transportation). Additionally, the grant supports mobile health units for testing, vaccine administration, and preventative health services, along with workforce expansions, capacity building, and personnel support to ensure the continuity of domestic violence services. Expected outcomes include increased access to COVID-19 testing and vaccines, reduced spread of the virus, and enhanced support systems for domestic violence survivors. Measurable results will likely involve the number of individuals tested, vaccinated, and reached through mobile health units, as well as improvements in survivor services. The ICJI's strategic priority is to give special emphasis to community-based projects carried out by nonprofit private organizations that operate shelters or provide counseling, advocacy, and self-help services to victims of family violence. The theory of change suggests that by providing these supplemental funds, ICJI can strengthen the public health response to COVID-19 while simultaneously supporting and sustaining the advocacy workforce dedicated to preventing and responding to the needs of domestic violence survivors during the ongoing public health emergency.

This funding opportunity supports short courses that train researchers in advanced mental health research skills, targeting graduate students, postdoctoral scholars, and early-career investigators across the nation.

This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, data calling, data sharing, data harmonization, and analysis that will support the generation of data from multi-ethnic cohorts for the Alzheimer's Disease Sequencing Project Follow-Up Study 2.0: The Diverse Population Initiative.Funding Opportunity Description Background This Funding Opportunity Announcement (FOA) is issued in response to National Alzheimer's Project Act (NAPA) milestones for the genetics of Alzheimer's disease (AD) and AD-related dementias (ADRD) in order to support the ongoing Alzheimer's Disease Sequencing Project (ADSP). The overarching goals of the ADSP are to: 1) identify new genes involved in AD/ADRD; 2) identify gene alleles contributing to increased risk for, or protection against, the disease; 3) provide insight as to why individuals with known risk factor genes escape from developing AD/ADRD; 4) identify potential avenues for therapeutic approaches and prevention of the disease; and 5) fully reveal the genetic architecture of AD/ADRD in multiple race and ethnicity categories. The samples for the ADSP were selected from well-characterized, diverse study cohorts of individuals both with and without an AD diagnosis as well as with and without known risk-factor genes. This study of human genetic variation and its relationship to health and disease involves a large number of study participants and aims to capture not only common single nucleotide variations, but also rare copy number and other structural variants that are increasingly thought to play an important role in complex diseases. This FOA uses the Office of Management and Budget (OMB) official categories of race and ethnicity. For the purposes of this FOA, ethnic categories (i.e., Hispanic/Latino) and racial categories (i.e., American Indian/Alaska Native; Asian; and Black/African American) will be referred to as diverse populations . Cohorts of participants from individual ethnic or race categories will be referred to as diversity cohorts . Individuals in diversity cohorts will be referred to as diversity participants . The ADSP has identified a large number of variations in the genomes of individuals affected with AD. The study population for these analyses was predominantly White. Lack of diversity in the sample set limits the possible clinical utility of emerging tools and methodological approaches for identifying potential therapeutics for a large proportion of the population. This, in turn, underscores the urgency to ensure appropriate representation of diverse populations to prevent potential gaps in the translation of research efforts to these populations. To this end, the initial ADSP findings will be pursued in diverse populations in the next phase of the study, called the ADSP Follow-Up Study (FUS) 2.0: The Diverse Population Initiative and referred to here as ADSP FUS 2.0. The long-term goals of the ADSP FUS 2.0 are to: 1) move the field closer to enabling prediction of who will develop AD; 2) fully characterize AD subtypes by studying endophenotypes in diverse populations; 3) better understand the differences in the genetic underpinnings of AD pathogenesis among diverse populations; and 4) identify specific therapeutic targets based upon diverse population. Important instances of unique AD/ADRD genetic variation have already been identified in epidemiological cohorts with Hispanic/Latino and Black/African American participants. Variants for AD are rare and can only be identified with a larger number of study participants. Variants occur at different frequencies in different populations, and certain risk variants may be much easier to detect in some populations. US diversity groups are not represented in ADSP data in sufficient numbers to enable meaningful study, so the genetics of these populations remain largely unstudied. Hispanics/Latinos, Blacks/African Americans, and Asians are the largest and fastest-growing minority groups in the US, and AD/ADRD imposes a high economic and social burden upon the US population. US Asian population ADSP genetic data are completely absent. Numbers of Hispanic/Latino and Black/African American participants in the US remain insufficient to provide statistical significance for identification of rare or very rare variants. Variants in the Alzheimer’s genome are largely rare or very rare in the population. It is estimated that for 80% certainty for single variant testing for rare variants, ~16,100 cases and ~16,100 controls are needed for a variant with a minor allele frequency of 0.5% in the population; single variant testing for rare variants indicate that for 90% certainty, ~18,500 cases and ~18,500 controls are needed for each population for a variant with a minor allele frequency of 1% in the population. To ensure that there are sufficient numbers of study participants to achieve statistical power for analysis of rare or vary rare variants in the three largest diversity cohorts AD/ADRD genome given the available funding, the primary focus of the ADSP FUS 2.0 will be on Hispanic/Latino, Black/African American, and Asian populations. Consortia should take advantage of cohorts already recruited or in planning for recruitment to obtain sufficient numbers; sharing diversity data across consortia is essential to the success of this effort. Investigators with cohorts representing other racial/ethnic categories, such as American Indians/Alaskan Natives, are encouraged to apply for funding separately under other NIA-supported FOAs. Sequencing of participants from founder populations such as those from Africa and Asia is allowed under this FOA in order to understand population substructure and ancestry-informative markers. A small amount of sequencing of Whites to bring significance to the 90% certainty of significance level will be allowed for rare or very rare variants for the US population; however, it is expected that the vast majority of sequencing in the ADSP FUS 2.0 will be done in Hispanics/Latinos, Blacks/African Americans, and Asians. Accelerated identification of AD/ADRD genes, gene clusters, and endophenotypes driven by genetic and ethnic/racial characteristics will move the field toward selection of participants with similar endophenotypes to improve outcomes of clinical trials. The community is now able to layer different types of data to identify these endophenotypes. Analytic approaches are being developed for analysis of structural and rare variants, endophenotypes, and cross-phenotype genetic analyses to modify and/or apply analytic methods to data that are increasingly complex. In order to identify optimal drug targets, the full landscape of genetic variants must be identified and characterized. Much work remains to develop analytic methods and resources to understand the functional significance of variants, particularly noncoding variants, in diverse populations. Under this funding opportunity announcement, studies that perform analysis of sequence data may include analysis of the functional genomic studies of regions of interest. Diversity datasets will need to be integrated and harmonized to fully annotate the AD genome. This may mean assembling annotation data such as that provided by ENCODE and similar approaches to help understand whether clusters of genes in the same network or with common function may be a component of the disease etiology that varies by ethnic and racial category. Applicants are encouraged to devise analysis plans to include data from genome wide association studies (GWAS) for AD; imputation analysis; ADSP whole exome and exome chip data, and whole genome AD sequencing efforts; related genetic data such as in deep (long read) sequencing analyses generated on AD subjects; and functional genomics data. Research Objectives NIA intends to support studies most likely to meet a major goal of this FOA: to identify and confirm a full set of rare variants contributing to AD/ADRD endophenotypes in diversity cohorts to enhance the probability of identifying potential therapeutic approaches for risk and prevention. Both sequencing and data analysis will be supported under this FOA. Applicants to this FOA for the ADSP FUS 2.0 should propose to: 1) sequence particular diverse study cohorts; 2) analyze either the entire dataset (cases and controls) or components of the dataset; or 3) both sequence and analyze these data. Justification for the choice of the approach must be provided. Applicants proposing to analyze only a component of the total cohort (i.e., selected cohorts or diverse subpopulations) should propose power calculations that support the likelihood of gene discovery. Applicants should design plans that clearly define which ADSP FUS 2.0 datasets, diverse subpopulations, and/or endophenotypes will be analyzed. Along with analysis of data funded under the present FOA, analysis plans for the ADSP FUS 2.0 should include data from diversity cohorts in the ADSP FUS funded under PAR-17-214, PAR-18-890, and PAR-19-234 where possible. The design and use of large-scale storage capacity with appropriate security and backup measures to support analytical capabilities should be considered. Successful applications are anticipated to involve research conducted by multidisciplinary teams of investigators and should describe a comprehensive plan to develop leading-edge, innovative approaches for the analysis of whole genome sequence (WGS) and related genetic data. Analysis should encompass the criteria set out by the ADSP FUS funded under PAR-17-214, "Analysis of Data from NIA's Alzheimer's Disease Sequencing Project Follow-Up Study (U01)." In particular, these criteria include ethnic/racial diversity; autopsy-confirmed cases/controls, especially for non-European ancestry; availability of longitudinal data; no age limit for cases; cases unrelated to each other; and availability of comparable controls. It is expected that the scientific environment in which the work will be done will contribute to the probability of success of the project and of the ADSP as a whole. Institutional support, equipment and other physical resources available to the investigators should be adequate for the project proposed, leveraging existing NIA-funded resources. Both the project itself and the ADSP should benefit from unique features of the scientific environment, subject populations, or collaborative arrangements. For applicants performing data analysis, it is expected that they will have the capacity to analyze whole-genome sequence data from sufficient numbers of affected and unaffected individuals to achieve statistical significance for rare or very rare variants in diverse groups. The successful milestone-driven ADSP FUS 2.0 application would consist of a group of researchers with expertise in the genetics of complex neurological diseases, including AD, and the field of whole genome sequencing, as well as statisticians and other experts who will participate in study design and analysis. Successful applicant(s) may be expected to collaborate not only within their own study, but also with other PD(s)/PI(s) funded under this and related FOAs. Engagement of existing NIA-supported infrastructure is considered essential to the success of the project, so applicants should plan to financially support the National Central Cell Repository for Alzheimer’s Disease (NCRAD); The American Genome Center (TAGC) at the Uniformed Services University for the Health Sciences (USUHS) or another NIA-approved, large-scale sequencing center; the Genome Center for Alzheimer's Disease (GCAD); and the NIA Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) for their efforts in the ADSP. Applicants should develop key quantitative milestones with a timeline for accomplishment. Quality control (QC) and data harmonization will be performed by GCAD. The order and process for data transfer, quality control checking, and data harmonization will be agreed upon by the ADSP as a whole and will follow closely the existing paradigm. Under the present FOA, the ADSP will improve the likelihood of analyzing sequence data on enough different examples of events that change the genetic architecture of AD such that these data, when analyzed with existing ADSP datasets, will enhance the ability to better understand the genetic underpinnings of AD and to obtain a better understanding of rare risk and protective variants. The availability of high-quality, extensive phenotypic information on study participants is a critical consideration. Study design should include analysis of data from study participants with quantitative trait measures to more clearly define endophenotypes. Similarly, participants whose data will be used as controls should be well characterized. Applications considered for funding must effectively leverage NIA and NIH investments in infrastructure to support studies related to the genetics of Alzheimer’s disease. The investigators funded under this FOA may utilize information from existing NIA- and NIH-funded research resources or other federal websites such as: The NIA Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) The Genome Center for Alzheimer's Disease (GCAD) The National Central Cell Repository for Alzheimer’s Disease (NCRAD) The National Alzheimer's Coordinating Center (NACC) The Alzheimer's Disease Genetics Consortium (ADGC) The Alzheimer's Disease Research Centers (ADRCs) Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) The Collaborative for Alzheimer’s Disease Research (CADRE) The Alzheimer's Disease Neuroimaging Initiative (ADNI) Alzheimer's Disease Related Dementias (ADRD) The National Alzheimer’s Project Act (NAPA) Other websites designed to store and distribute data related to AD

This grant provides funding to nonprofit organizations and local entities in rural Missouri to improve mental health services and programs for youth aged 0-21.

This grant provides funding to organizations that will educate and promote financial support for living organ donors, particularly in underserved communities, to increase awareness and access to organ donation services.

The "Building Healthy Communities: Reducing Health Disparities in Elementary Schools" program, funded by Blue Cross Blue Shield of Michigan, is a school-based initiative designed to address the social determinants of health contributing to widespread disparities across Michigan communities. This program aligns with a broader mission to foster healthier environments and reduce health, education, and economic disparities at the elementary school level. It recognizes the critical link between social determinants and a child's overall well-being and academic success, positioning schools as key environments for intervention. The primary beneficiaries of this program are elementary school children, educators, and the broader school community within districts most affected by health, education, and economic disparities in Michigan. The impact goals are multifaceted, aiming to facilitate healthier school environments, assist educators in recognizing and addressing issues of trauma in children, improve children's mental health, and ultimately increase school attendance and academic achievement. By focusing on these areas, the program seeks to create a more supportive and equitable learning environment for all students. The program's priorities and focuses include providing necessary resources and professional development to educators. This involves equipping them with the tools to identify and respond to trauma, promote mental well-being, and implement strategies that enhance overall school health. The core strategy is to engage entire school districts, from central administrators to individual teachers, to ensure a comprehensive and sustained commitment to the program's objectives. This district-wide approach is crucial for integrating the program effectively into the existing educational framework. Expected outcomes and measurable results include a significant improvement in children's mental health, a demonstrable increase in school attendance, and enhanced academic achievement. The program also aims to create measurably healthier school environments and reduce the impact of trauma on children's education. While specific metrics are not detailed, the emphasis on state and national data to identify and recruit participating districts suggests a data-driven approach to tracking progress and demonstrating impact on reducing disparities in health, education, and the economy within targeted communities.

This funding opportunity provides financial support for research projects that develop and test nonopioid pain management strategies for Veterans and military personnel, focusing on integrating these approaches into standard healthcare practices.

This funding opportunity provides financial support to organizations in Ohio that focus on improving children's vision health and safety, particularly for underserved populations, through initiatives like vision screening, protective eyewear, and educational programs.

This funding opportunity supports research projects that develop and test innovative interventions for individuals with substance use disorders involved in the criminal justice system, particularly focusing on improving treatment access and outcomes in diverse settings.

This funding opportunity supports nonprofit and government organizations that provide integrated substance use disorder treatment and supportive services for pregnant and parenting women, including adolescents, to improve their health and recovery outcomes.